Get started
Author

Hareesh B. Nair

Observed names: H.B. Nair, Hareesh B. Nair, Hareesh B Nair, Hareesh Nair
ORCID: 0000-0002-0364-7518
Observed ORCID: 0000-0002-0364-7518
OpenAlex ID: A5102791014
Targeting LIF/LIFR signaling in cancer
2021 · Suryavathi Viswanadhapalli, Kalarickal V. Dileep, et al. · Genes & Diseases · 131
PDF
EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer
2019 · Suryavathi Viswanadhapalli, Yiliao Luo, et al. · Molecular Cancer Therapeutics · 77
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer
2021 · Weiwei Tang, Kumaraguruparan Ramasamy, et al. · Cell Death Discovery · 42
PDF
The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights
2022 · Sushanta Halder, Seema Parte, et al. · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 40
PDF
Utilizing cell line-derived organoids to evaluate the efficacy of a novel LIFR-inhibitor, EC359 in targeting pancreatic tumor stroma
2018 · Bradley R. Hall, Andrew Cannon, et al. · Genes & Cancer · 31
PDF
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
2021 · Mengxing Li, Suryavathi Viswanadhapalli, et al. · Communications Biology · 29
PDF
Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis
2024 · Behnam Ebrahimi, Suryavathi Viswanadhapalli, et al. · npj Precision Oncology · 22
Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer
2025 · Rakesh Bhatia, Imran Khan, et al. · npj Precision Oncology · 13
PDF
Significance of LIF/LIFR Signaling in the Progression of Obesity-Driven Triple-Negative Breast Cancer
2024 · Lois Randolph, Jaitri Joshi, et al. · Cancers · 4
Esters of levonorgestrel and etonogestrel intended as single, subcutaneous-injection, long-lasting contraceptives
2018 · Frederick A. Meece, Gulzar Ahmed, et al. · Steroids · 4
PDF
1205Lu Human Metastatic Melanoma Cells, not Human!
2013 · Hareesh B. Nair · Journal of Cancer Science & Therapy · 4
PDF
Discovery and preclinical pharmacology of EC330: A first-in-class leukemia inhibitory factor (LIF) inhibitor
2016 · H.B. Nair, B. Santhamma, et al. · European Journal of Cancer · 3
Abstract LB-208: First-in-class steroidal leukemia inhibitory factor (LIF) inhibitor in targeted cancer therapy
2016 · Hareesh B. Nair, Bindu Santhamma, et al. · Cancer Research · 1
Abstract 3110: Targeting LIF/LIFR signaling with EC359 overcomes chemoresistance and enhances chemotherapy efficacy in ovarian cancer
2026 · Sonal R. Chaudhari, Baskaran Subramani, et al. · Cancer Research
EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling
2025 · William C. Arnold, Durga Meenakshi Panneerdoss, et al. · Biomolecules
PDF
Abstract LB435: Novel MDK targeted therapy for treating triple negative breast cancer
2025 · Megharani Mahajan, Alondra L. Rodriguez Sanchez, et al. · Cancer Research
Abstract 5989: Investigating the potential of EC359 in inducing ferroptosis for the treatment of type I and type II endometrial cancers
2025 · Emily J. Aller, Xue Yang, et al. · Cancer Research
Abstract 5985: Low-grade serous ovarian cancer is effectively treated with a combination of trametinib and LIFR inhibitor therapeutics
2025 · William C. Arnold, Durga Meenakshi Panneerdoss, et al. · Cancer Research
Novel EC914 Targeting the LIFR/DDX21/Fibrillarin Axis Is a Potential Therapeutic Strategy To Overcome Adaptive Chemo-Persistence in Prostate Cancer
2025 · Sushanta Halder, Shobhit Lall, et al. · SSRN Electronic Journal
Abstract 4688: EC359, A new therapeutic drug for the treatment of low grade serous ovarian cancer
2024 · Yasmin Lyons, William Cole Arnold, et al. · Cancer Research
Abstract 5986: Significance of LIF/LIFR axis in the progression of inflammatory breast cancer
2024 · Bianca Romo, Zenaida Fuentes, et al. · Cancer Research
Abstract 4966: Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapy
2023 · Behnam Ebrahimi, Suryavathi Viswanadhapalli, et al. · Cancer Research
Data from EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer
2023 · Suryavathi Viswanadhapalli, Yiliao Luo, et al.
Supplementary Figures S1-10 and Table S1 from EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer
2023 · Suryavathi Viswanadhapalli, Yiliao Luo, et al.
PDF
Supplementary Table and Figure Legend from Elevated Expression of the Oncogene c-fms and Its Ligand, the Macrophage Colony-Stimulating Factor-1, in Cervical Cancer and the Role of Transforming Growth Factor-β1 in Inducing c-fms Expression
2023 · Nameer Kirma, Luciano S. Hammes, et al.
Works count: 34
Citation count: 401
H-index: 8
I10-index: 8
Year
Topic
Type